scholarly journals MALIGNANT PROLIFERATING TRICHILEMMAL TUMOR ONE CASE AND LITERATURE REVIEW

2021 ◽  
Vol 9 (11) ◽  
pp. 1265-1268
Author(s):  
O. Elatiqi ◽  
◽  
Z. Alami ◽  
I. Zinedinde ◽  
I. Yafi ◽  
...  
Keyword(s):  
Lymph Node ◽  
Literature Review ◽  
Lymph Node Involvement ◽  
Node Dissection ◽  
Trichilemmal Cyst ◽  
Node Involvement ◽  
Aggressive Tumors ◽  
Proliferating Trichilemmal Tumor ◽  
Radio Chemotherapy ◽  
Malignant Proliferating Trichilemmal Tumor

Proliferating trichilemmal tumors (PTTs) are uncommon lesions. PTT is thought to originate from the trichilemmal cyst (TC) and have the potential for malignant transformation, at which point it is termed a malignant proliferating trichilemmal tumor (MPTT). we report an observation of a 55-year-old lady patient presenting with a malignant proliferative trichilemmal tumor, emphasizing the aggressive, rapidly extensible and metastatic character. MPTTare aggressive tumors with a bad prognosis, the treatment of which is based on surgery with margins of 1 cm, lymph node dissection in the event of lymph node involvement and radio-chemotherapy.

scholarly journals Squamous cell carcinoma of the breast: case report

Mastology ◽  
2020 ◽  
Vol 30 (Suppl 1) ◽  
Author(s):  
Daniel Carbonieri Batista de Oliveira ◽  
Carlos Elias Fristachi ◽  
Eveline de Abrantes Silva ◽  
Fabio Francisco de Oliveira Rodrigues ◽  
Rodrigo Macedo da Silva
Keyword(s):  
Squamous Cell Carcinoma ◽  
Lymph Node ◽  
Literature Review ◽  
Cell Carcinoma ◽  
Lymph Node Involvement ◽  
Axillary Lymph ◽  
Her2 Expression ◽  
Node Dissection ◽  
Carcinoma Of The Breast ◽  
Node Involvement

Introduction: Primary squamous cell carcinoma of the breast (SCCB) is a rare malignant neoplasm, confirmed when at least 90% of the cells are of the squamous type. It represents about 1% of all cases of breast carcinomas. The literature has few reports on the subject, showing that SCCB has no specific radiological features. Objective: To report a case of SCCB diagnosed at the Instituto do Câncer Doutor Arnaldo Vieira de Carvalho. Method: We conducted a review of medical records, photographic records, and a literature review. Result: An 82-year-old woman had a small breast lesion in 2016, but for fear, she hid it until the end of 2018. In the beginning, the lesion was treated with topical corticosteroids and monitored at a community health clinic. After worsening, she was referred to a specialized service. Upon physical examination, the lesion was firm, exophytic, friable, and non-nodular, with fibroelastic axillary lymph nodes of up to 1.5 cm. The mammography from October 2018 was classified as BI-RADS® 2 and the breast ultrasound as BI-RADS® 3, showing only skin lesion. Incisional biopsy revealed SCCB with immunohistochemistry positive for cytokeratin-14 and protein p63 and negative for hormone receptors (HR) and HER2 expression. She underwent central quadrantectomy with axillary lymph node dissection in April 2019, confirming SCCB and without lymph node involvement (0/14). After 5 months, the patient showed lesions suggestive of herpes zoster, confirmed by serology. Without improvement with acyclovir, a new biopsy was performed, which confirmed local recurrence. In December, she started radiotherapy, but the lesion progressed to necrosis, papules, and extended to the dorsum, accompanied by intense pain. Chemotherapy with cisplatin 30 mg/m² weekly was proposed, with partial response. Conclusion: SCCB at diagnosis has >4 cm, and 50% of them have associated cysts. Usually, it has a high grade and is negative for HR and HER2 expression. Mammographic images do not have specific features, explaining the large lesions during screening. The literature review revealed that 70% of SCCB patients do not have lymph node involvement, but due to its unpredictable spread, lymph node dissection might be conducted for staging. It is considered an aggressive disease with an uncertain prognosis, and the data available is not enough to provide options to prevent recurrence. SCCB is rare, has a poor prognosis, and surgery is the most accepted initial treatment. In the case of recurrence, the treatment of choice is radiotherapy associated with cisplatin-based chemotherapy and anti-PD-L1 immunotherapy (cemiplimab), which was recently approved by the Food and Drug Administration (FDA).

What is the yield of regional lymph node dissection following sentinel lymph node involvement in patients with breast cancer?

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10782-10782
Author(s):  
M. Ortega ◽  
M. Ruiz-Echarri ◽  
E. Prats ◽  
R. Lastra ◽  
E. Aguirre ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Lymph Node Dissection ◽  
Regional Lymph Node ◽  
Tumour Size ◽  
Median Number ◽  
Lymph Node Involvement ◽  
Node Dissection ◽  
Regional Lymph Node Dissection ◽  
Node Involvement

10782 Background: Sentinel lymph node is a minimally invasive and accurate staging procedure for patients with invasive breast cancer. Histological SLN involvement with cancer cells requires regional lymph node dissection. Aim: To verify if subgroups of patients with sentinel lymph node involvement in which the risk of histological involvement of additional regional lymph nodes is minimal can be identified. Methods: Ninety six consecutive patients with invasive breast cancer and tumour size less than two centimeters by mammography, had lymphoscintigraphy with colloidal 99Tc and radioisotope-guided sentinel lymph node biopsy in the University Hospital of Zaragoza from 1999 to 2005.Pathological assessment included serial sections of the sentinel lymph node with inmunohistochemistry for cytokeratins in selected cases.39 patients had histological involvement and are presented in this analysis. Results: All 39 patients were females. Median tumour size was 20 mm (range 5–52) Median number of resected sentinel lymph node was 2 (range 1–5) Median number of involved sentinel lymph node was 1 (range 1–4) Regional lymph node dissection was performed in all patients (Axillary dissection in 31; internal mammary dissection in 1, both in 7). Median number of nodes was 13 (range 2–34) At least 1 additional involved lymph node was found in 19 patients (48%) We have correlated patient age, menopausal status, pathological tumour size, histological grade, estrogen receptors, progesterone receptors and Her2 with the risk of histological lymph node involvement in regional lymph node dissection. Conclusions: Tumour size was significantly associated to such risk: No significant financial relationships to disclose.

Ugly is not only skin deep: A case of osteogenic melanoma.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e20009-e20009
Author(s):  
Joshua C.M. Williams ◽  
Natale Tate Sheehan ◽  
Pierre DeDelva ◽  
Jennifer Barr
Keyword(s):  
Lymph Node ◽  
Malignant Melanoma ◽  
Lymph Node Dissection ◽  
Lower Lobe ◽  
Lymph Node Involvement ◽  
Node Dissection ◽  
Inguinal Lymph Node Dissection ◽  
Left Lower Extremity ◽  
Node Involvement ◽  
Initial Biopsy

e20009 Background: Although the incidence of malignant melanoma is high, the incidence of metaplastic malignant melanoma is low. Within the various subtypes of malignant metaplastic melanoma, the manifestation of osteogenic melanoma remains a rarer event. Current review of the literature reveals only 12 reported cases. Of these reported cases, scant discussion is made on treatment whereas the histopathology is discussed in great detail. Methods: We present the case of a 64 year old Caucasian man that was diagnosed with synchronous tumors of the foot and lung. Initial biopsy of the foot revealed metastatic osteogenic melanoma. As a result of the initial biopsy results and imaging, the patient underwent a right lower lobe resection and lymph node dissection followed by a left lower extremity Pirigoff’s amputation and inguinal lymph node dissection. Results: Immunohistochemical staining of the extirpated tissue from the lung revealed strong reactivity to S100, vimentin, Sox10, diffuse reactivity to low molecular weight cytokeratin and HMB-45/MART-1 and no lymph node involvement. Whereas the IHC of the extirpated tissue of the left foot remained consistent with the initial biopsy of strong reactivity to S100 and MART-1 and negative to pancytokeratins, CD34, Desmin, and SMA. Conclusions: Given the features of the patient’s pathology and resected metastatic disease, he was administered adjuvant alpha interferon therapy.

Sign in / Sign up

Export Citation Format

Share Document